MediciNova (MNOV) Gets Notice of Allowance in Japan for MN-166 Patent Application
Tweet
Share
E-mailGet Alerts MNOV Hot Sheet
Join SI Premium – FREE
MediciNova, Inc.(Nasdaq: MNOV) has received a Notice of Allowance from the Japanese Patent Office for a pending patent application, which covers the use of ibudilast (MN-166) for the treatment of multiple forms of chronic neuropathic pain. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than the end of 2025 and covers a method of treating certain existing chronic neuropathic pain conditions by administering ibudilast either alone or in combination with other active ingredients, such as analgesic drugs. Some of the chronic neuropathic pain conditions covered includes those following herpes infection (postherpetic neuralgia), spinal cord injury, stroke, and cancer chemotherapy and other syndromes covered include fibromyalgia and complex regional pain. The allowance of these claims in Japan compliments company-owned patent rights for methods of treating existing chronic neuropathic pain conditions with ibudilast administration that are already awarded in the United States and Canada.
A patent maturing from this allowed patent application is expected to expire no earlier than the end of 2025 and covers a method of treating certain existing chronic neuropathic pain conditions by administering ibudilast either alone or in combination with other active ingredients, such as analgesic drugs. Some of the chronic neuropathic pain conditions covered includes those following herpes infection (postherpetic neuralgia), spinal cord injury, stroke, and cancer chemotherapy and other syndromes covered include fibromyalgia and complex regional pain. The allowance of these claims in Japan compliments company-owned patent rights for methods of treating existing chronic neuropathic pain conditions with ibudilast administration that are already awarded in the United States and Canada.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- loanDepot receives NYSE non-compliance notice over stock price
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
